Nkarta announces presentation of preclinical data on nkx019, engineered nk cell therapy candidate targeting cd19, at the annual meeting of the society for immunotherapy of cancer

South san francisco, calif., nov. 09, 2020 (globe newswire) -- nkarta, inc. (nasdaq: nktx), a clinical-stage biopharmaceutical company developing engineered natural killer (nk) cell therapies to treat cancer, today announced a preclinical update on nkx019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (nk) cells engineered with a membrane-bound form of il15 and a chimeric antigen receptor (car) targeting the cd19 antigen.
NKTX Ratings Summary
NKTX Quant Ranking